ADIL Latest Press Releases

-- October 28, 2026 --

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis Globe Newswire 4:02 PM

-- October 26, 2026 --

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer Globe Newswire 8:00 AM

-- October 16, 2026 --

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis Globe Newswire 7:00 AM

-- September 30, 2026 --

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:46 PM

-- August 25, 2026 --

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 17, 2026 --

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Globe Newswire 7:00 AM

-- June 16, 2026 --

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing Globe Newswire 8:00 AM

-- June 11, 2026 --

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing Globe Newswire 11:43 AM

Market Data Delayed 15 Minutes